Rifampicin Mono-Resistant Tuberculosis-A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control

Jason H Malenfant; Timothy F Brewer

doi:10.1093/ofid/ofab018

Rifampicin Mono-Resistant Tuberculosis-A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control

Open Forum Infect Dis. 2021 Jan 28;8(2):ofab018. doi: 10.1093/ofid/ofab018. eCollection 2021 Feb.

Authors

Jason H Malenfant¹, Timothy F Brewer^{2

3}

Affiliations

¹ Public Health & Preventive Medicine Program, UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
² Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.
³ Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA.

Abstract

Tuberculosis (TB) remains the leading cause of death by an infectious pathogen worldwide, and drug-resistant TB is a critical and rising obstacle to global control efforts. Most scientific studies and global TB efforts have focused on multidrug-resistant TB (MDR-TB), meaning isolates resistant to both isoniazid (INH) and rifampicin (RIF). Newer diagnostic tests are resulting in an increasing awareness of RIF-resistant TB in addition to MDR disease. To date, RIF resistance has been assumed to be synonymous with MDR-TB, but this approach may expose TB patients with RIF mono-resistance disease to unnecessarily long and toxic treatment regimens. We review what is currently known about RIF mono-resistant TB, its history and epidemiology, mechanisms of RIF resistance, available diagnostic techniques, treatment outcomes reported globally, and future directions for combatting this disease.

Keywords: rifampicin mono-resistant tuberculosis; tuberculosis.

Publication types

Review